Exelixis EBITDA 2011-2025 | EXEL

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Exelixis

2025	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
633 M	197 M	222 M	300 M	378 M	378 M	447 M	167 M	-95 M	-119 M	-214 M	-196 M	-102 M	88.4 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
633 M	-214 M	149 M

Quarterly EBITDA Exelixis

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	194 M	-	-	-	35.8 M	-	-	-	35.7 M	-	97.5 M	93 M	87.7 M	24.3 M	63.3 M	130 M	-1.38 M	77.3 M	-35.8 M	79.9 M	55 M	-	122 M	96 M	86.5 M	112 M	128 M	86.9 M	117 M	37.4 M	82 M	27.7 M	20.5 M	38.9 M	8.02 M	-24.7 M	-48.9 M	-31.6 M	-34.7 M	-30.6 M	-22.5 M	-46.2 M	-48.6 M	-60.6 M	-64.5 M	-	-53.5 M	-49.7 M	-33.2 M	-	-21.4 M	-30.1 M	-21.1 M	-	84.7 M	-14.1 M	-21.8 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
194 M	-64.5 M	28.8 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Arbutus Biopharma Corporation ABUS	-76.7 M	$ 4.85	2.87 %	$ 805 M	Canada
Aclaris Therapeutics ACRS	-141 M	$ 3.21	-1.23 %	$ 248 M	USA
AlloVir ALVR	-200 M	-	4.14 %	$ 49.1 M	USA
Aptevo Therapeutics APVO	-24.2 M	$ 1.06	-6.64 %	$ 293 K	USA
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Ascendis Pharma A/S ASND	-452 M	$ 215.41	-2.27 %	$ 5 B	Danmark
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Alterity Therapeutics Limited ATHE	-17.3 M	$ 3.15	-3.85 %	$ 7.58 B	Australia
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
BioVie BIVI	-17.8 M	$ 1.43	-1.39 %	$ 2.11 M	USA
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	-130 M	-	-15.15 %	$ 60.3 M	Britain
BioNTech SE BNTX	15.3 B	$ 94.02	-0.84 %	$ 27.2 B	Germany
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Alpine Immune Sciences ALPN	-57.6 M	-	-	$ 2.17 B	USA
Ampio Pharmaceuticals AMPE	122 K	-	-11.43 %	$ 502 K	USA
Amphastar Pharmaceuticals AMPH	234 M	$ 26.2	3.68 %	$ 1.27 B	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
Anika Therapeutics ANIK	-81.2 M	$ 9.59	0.31 %	$ 141 M	USA
Can-Fite BioPharma Ltd. CANF	-10.1 M	$ 0.27	-6.08 %	$ 588 M	Israel
Arena Pharmaceuticals ARNA	-620 M	-	-6.81 %	$ 3.04 B	USA
Athersys ATHX	-85.6 M	-	3.77 %	$ 22.4 M	USA
Acer Therapeutics ACER	-24.5 M	-	2.71 %	$ 14 M	USA
Catalyst Biosciences CBIO	-66.2 M	$ 13.48	-4.36 %	$ 887 M	USA
Avenue Therapeutics ATXI	-11.3 M	-	-52.27 %	$ 4.45 M	USA
AVROBIO AVRO	10.8 M	-	1083.1 %	$ 745 M	USA
Axon Enterprise AXON	107 M	$ 549.1	-2.69 %	$ 41.6 B	USA
Ayala Pharmaceuticals AYLA	-37.3 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	-2.45 M	$ 2.4	4.34 %	$ 15.1 M	USA
AstraZeneca PLC AZN	1.06 B	$ 91.04	1.35 %	$ 96.9 B	Britain
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Brickell Biotech BBI	-6.32 M	-	-5.38 %	$ 6.06 M	USA
Burford Capital Limited BUR	242 M	$ 8.87	-1.55 %	$ 1.45 B	Britain
BeiGene, Ltd. BGNE	-396 M	-	0.49 %	$ 251 B	Cayman-islands
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-679 M	$ 11.23	-2.69 %	$ 726 M	USA
Biogen BIIB	673 M	$ 174.94	0.48 %	$ 25.5 B	USA
Abeona Therapeutics ABEO	-44.8 M	$ 5.07	-5.5 %	$ 108 M	USA
Celldex Therapeutics CLDX	-192 M	$ 27.11	-1.47 %	$ 1.75 M	USA
ADiTx Therapeutics ADTX	-27.2 M	$ 1.66	-25.84 %	$ 21.9 K	USA
Cellectar Biosciences CLRB	-38.8 M	$ 3.36	-7.32 %	$ 41.1 M	USA
Bellicum Pharmaceuticals BLCM	-27 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	-89 M	-	-7.31 %	$ 87 M	USA
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Завод ДИОД DIOD	85.9 M	-	-	-	Russia
Фармсинтез LIFE	-22.6 M	-	-	-	Russia